Alumis Inc. Common Stock
NASDAQ:ALMSBiotechnology
+$0.21 today
- Market cap
- $626.47M
- Beta
- -0.54
- P/E (TTM)
- -12.2
- EPS (TTM)
- -$1.90
Volume 1.86M
Average 1.31M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
Alumis Inc. Common Stock
NASDAQ:ALMS
Intrinsic Alpha fair value
Locked
Current Price
$4.84
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A2 analysts |
| Revenue | N/A | N/A | N/A | +105.6% (5yr)5 analysts |
| Net Income | N/A | N/A | N/A | N/A5 analysts |
| EBIT | N/A | N/A | N/A | N/A — |
Analysis
Forward estimates point to Revenue at +105.6% (5yr), giving you a quick read on expected growth from here.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
AnaptysBio, Inc. NASDAQ:ANAB | $1.38B | $46.25 | Overvalued | -59.7 | +84.88% |
Odyssey Therapeutics, Inc. NASDAQ:ODTX | $920.02M | $19.14 | Not rated | — | — |
Rigel Pharmaceuticals, Inc. NASDAQ:RIGL | $837.18M | $44.46 | Undervalued | 1.7 | -7.14% |
Aclaris Therapeutics, Inc. NASDAQ:ACRS | $621.76M | $3.92 | Not rated | -8.2 | +35.74% |
Avalo Therapeutics, Inc. NASDAQ:AVTX | $448.71M | $7.76 | Not rated | -3.6 | -60.39% |
AgomAb Therapeutics N.V. American Depositary Shares NASDAQ:AGMB | $313.22M | $6.36 | Not rated | -7.1 | — |
Artiva Biotherapeutics, Inc. NASDAQ:ARTV | $198.22M | $4.01 | Not rated | -2.7 | -0.77% |
InflaRx N.V. NASDAQ:IFRX | $172.42M | $1.17 | Not rated | -2.7 | -9.45% |
Tiziana Life Sciences Ltd NASDAQ:TLSA | $72.52M | $0.57 | Not rated | -4.0 | -63.39% |
Aldeyra Therapeutics, Inc. NASDAQ:ALDX | $38.86M | $0.64 | Not rated | -4.2 | -81.67% |
Continue the stock analysis
Jump to another research area for this company.